Welcome to our dedicated page for Avicanna news (Ticker: AVCNF), a resource for investors and traders seeking the latest updates and insights on Avicanna stock.
Avicanna Inc. (AVCNF) is a commercial-stage international biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived, cannabinoid-based products. The Avicanna news feed on Stock Titan highlights company announcements across its medical cannabis, pharmaceutical, and active pharmaceutical ingredient activities.
Investors and observers can follow updates on Avicanna’s RHO Phyto™ medical cannabis formulary, including clinical and real-world evidence results related to topical creams, transdermal gels, and other cannabinoid-based formulations. News items also cover the MyMedi.ca medical cannabis care platform, which the company describes as a patient-focused service with pharmacist-led support and collaborations with public and private payers.
Avicanna regularly reports milestones in its pharmaceutical pipeline, such as the indication-specific drug registration of Trunerox™ in Colombia for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome, as well as patents granted for topical and oral cannabinoid drug delivery technologies. Additional coverage includes export activities and certifications at its majority-owned subsidiary Santa Marta Golden Hemp SAS, which supplies CBD, THC, and CBG under the Aureus Santa Marta™ brand.
By monitoring Avicanna news, readers can see disclosures on financial performance, clinical collaborations with academic and clinical institutions, regulatory approvals, and international partnerships. This page brings together these company-issued updates in one place, making it easier to review Avicanna’s ongoing work in cannabinoid-based medicine and medicinal and botanical manufacturing.
Avicanna (OTCQX: AVCNF) welcomed the December 19, 2025 executive order to reclassify cannabis from Schedule I to Schedule III and provided a scientific update on 2025 R&D, clinical development, and medical affairs progress.
Key highlights include a real-world evidence study with University Health Network that has enrolled approximately 450 patients, the start of a Phase II randomized controlled trial for arthritic pain in December 2025, a newly granted USPTO patent, and translation of proprietary technologies including PwdRx into commercial stage, plus expanded medical affairs and patient-access initiatives.
Avicanna (OTCQX: AVCNF), through its subsidiary Santa Marta Golden Hemp SAS (SMGH), has completed its first export of non-psychoactive CBD dominant cannabis flower to Switzerland. This milestone marks SMGH's first organic certified flower export and represents the 20th international market for Aureus-branded products and 23rd market for all Avicanna products.
The export follows the company's 2024 infrastructure and practice improvements at SMGH, aimed at expanding its Aureus-branded premium organic flower portfolio. The shipment included three proprietary cannabis varieties registered in Colombia, targeting growing demand in European and Australian medical cannabis markets.
Avicanna LATAM SAS (OTC:AVCNF) has partnered with Harrington Wellness to launch re+PLAY CBD wellness brand topicals across the United States. The collaboration introduces two initial products: a 3% CBD localized cream and a 2% CBD and 1% CBG transdermal gel utilizing Avicanna's patented deep tissue technology.
The products, developed through collaboration between scientists, athletes, doctors, and certified athletic trainers, will be available through replaycbd.com and select U.S. retailers in September 2025. The CBD and CBG ingredients are sourced from USDA organic certified hemp cultivated by Avicanna's subsidiary Santa Marta Golden Hemp and manufactured in Colombia.
Avicanna (AVCNF) reported strong financial results for 2024, with revenue reaching $25.5 million, marking a 52% increase from 2023. The company achieved significant improvements in profitability, with gross profits rising 94% to $12.9 million and gross margins expanding to 51%.
Key operational highlights include the initiation of a 1,000-patient medical cannabis study, expansion to 42 proprietary commercial SKUs, and completion of several clinical studies, including research on epidermolysis bullosa and musculoskeletal pain. The company's adjusted EBITDA loss narrowed by 68% to $1.4 million, and they successfully repaid $1.3 million in debentures.
Notable achievements include obtaining drug registration in Colombia for Trunerox™, delivering proprietary topical products to a multinational pharmaceutical company, and securing two new US patents for their cannabinoid delivery technologies.
Avicanna (TSX: AVCN) (OTCQX: AVCNF) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma. The partnership involves establishing a joint Scientific and Medical Affairs Committee focused on enhancing understanding of medical cannabis access and applications in Canada.
The collaboration will focus on working with Canadian healthcare professionals to facilitate research studies and provide evidence-based educational resources. Key objectives include engaging with the medical community, patients, advocacy groups, and insurers to understand medical cannabis access challenges. The initiative will utilize Avicanna's medical cannabis platform, Mymedi.ca, to improve access and patient support.
Avicanna has announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. US 11,998,632 B2 for their self-emulsifying drug delivery system (SEDDS) oral cannabinoid compositions and methods for treating neuropathic pain. This patent issuance marks a significant milestone for Avicanna, a biopharmaceutical company specializing in plant-derived cannabinoid-based products. The company highlights the importance of cannabinoids in advanced drug delivery systems and looks forward to further clinical applications and collaborations with healthcare providers to benefit patients suffering from neuropathic pain.
Avicanna reports its first positive Adjusted EBITDA quarter in Q1 2024, achieving a $17k EBITDA, a significant improvement from a $1.28 million loss in Q1 2023. The company posted record quarterly revenue of $6.45 million, a 451% year-over-year increase, and a 6.5% rise from Q4 2023. Gross margins improved to 51%, up from 42% in Q1 2023. Cash provided from operations was $122k, compared to a $2.05 million usage in Q1 2023. Avicanna expanded its medical cannabis offerings in Canada and received marketing authorization for Trunerox™ in Colombia for treating severe seizures. It also secured supply and licensing agreements for Europe and initiated a research collaboration with a European pharmaceutical company, focusing on cannabinoid delivery technology.
Avicanna Inc. announced the results of a study conducted at The Hospital for Sick Children on the use of their RHO Phyto™ branded Ultra CBD Topical Cream in patients with Epidermolysis Bullosa. The study evaluated wound healing, pain, and itch, with 55% of patients showing improvements in wound healing and 45% displaying wound stability after one month of daily application. The study results will be presented at Avicanna's symposium on May 13th, highlighting the positive outcomes of the CBD cream in treating EB.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Avicanna (AVCNF)?
What is the market cap of Avicanna (AVCNF)?
